When López-Otín and colleagues published “The Hallmarks of Aging” in Cell in 2013, they did something the field of biogerontology had quietly needed for decades: they created a framework. Nine interconnected processes, from genomic instability and telomere attrition...
The biotech M&A 2026 market has entered what many analysts are already calling a breakout year. In the first four months of 2026 alone, pharma and biotech companies have signed deals worth approximately $84 billion, and the pipeline of transactions shows no sign...
Thesis Early-stage life science development is increasingly constrained not by lack of data, but by fragmented, multi-scale evidence that resists straightforward interpretation. AI systems can assist in structuring this complexity – through literature triage,...
In the high-stakes world of drug discovery and biomanufacturing, the spotlight typically shines on breakthrough modalities, venture rounds, and FDA milestones. Yet, behind every clinical success is a physical environment that either accelerated the science or quietly...
In fast-moving areas like radiopharmaceuticals and precision immunology, the biggest portfolio risk is often not uncertainty itself, but false certainty created by mismatched benchmarks. As life sciences enters a more disciplined cycle, one pattern shows up across...
The Billion-Dollar Race to Slow Ageing Billions of dollars are pouring into the idea that ageing is a disease we can treat. The longevity biotech sector attracted $8.49 billion in private investment across 325 deals in 2024, according to Longevity.Technology's Annual...
The England Rare Diseases Action Plan 2026 outlines how the Department of Health and Social Care and partner organisations are delivering commitments under the UK Rare Diseases Framework to improve outcomes for people living with rare conditions in England. The report...
As the echoes of the COVID-19 crisis fade, humanity remains on high alert for the inevitable next pathogen. What if we could dissect viruses down to their atomic core, revealing chinks in their armor that lead to revolutionary treatments? Drawing from my 12+ years as...
The life sciences sector is experiencing a fundamental reshaping of its innovation geography as funding pressures, policy shifts, and geopolitical tensions redraw the competitive landscape across continents. While research funding constraints in the United States...
Marking its success San Diego debut earlier this month, Phacilitate’s Advanced Therapies Week (ATW), brought together leaders, innovators, and industry stakeholders from around the world for a dynamic showcase of progress in cell and gene therapies (CGT). From...
Kelly Nguyen is a molecular biologist and Group Leader in the Structural Studies Division at the MRC Laboratory of Molecular Biology (LMB), where her research aims to uncover how telomeres are structured, maintained and regulated by the enzyme telomerase. Telomeres...
In the pharmaceutical industry, the statistics of failure are so familiar they have become clichés: it takes ten years and two billion dollars to bring a new drug to market, with a failure rate in clinical trials hovering near 90%. While much of this attrition is...
After decades of promise and setbacks, advanced manufacturing platforms and robust Phase 2/3 trials are demonstrating whether MSCs can deliver transformative treatments for high-burden diseases Mesenchymal stromal cells (MSCs) have been called the most promising...
Generative AI has already changed what is possible in protein engineering. In the last few years, the field has moved from predicting protein structures to proposing entirely new proteins, often with experimentally verified folding and binding, at a pace that was...
Antibiotics are one of the greatest success stories in modern medicine. They transformed once-deadly infections into treatable illnesses, made routine surgery possible, and helped extend human life expectancy worldwide. From treating pneumonia to protecting patients...
“Hypoxia” used to be nothing but a niche biology topic. Today it is quietly becoming standard infrastructure in labs. Two forces are converging. Regulators and funders are nudging R&D away from default animal studies and toward human-relevant evidence. At the...
Scientists have uncovered how plants produce mitraphylline, a rare natural compound with demonstrated anti cancer properties, shedding new light on the biological machinery behind one of nature’s most complex chemical products. By identifying the key enzymes involved...
Biotech is showing early signs of life after a prolonged funding winter, but for many early-stage companies, conditions remain unforgiving. Years of low valuations, high borrowing costs and regulatory uncertainty have reshaped investor behaviour, with capital scarce...